Genetic polymorphisms and activity of cholesterol ester transfer protein (CETP): Should we be measuring them?

Clinical Chemistry and Laboratory Medicine

Volumn 38, Issue 10, 2000, Pages 945-949

  Ordovas, J M ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Cholesteryl ester transfer protein; Coronary heart disease; Genetic polymorphisms; High density lipoproteins; Lipoproteins

Indexed keywords

4 PHENYL 5 TRIDECYL 4H 1,2,4 TRIAZOLE 3 THIOL; 4 PHENYL 5 TRIDECYL4H 1,2,4 TRIAZOLE 3 THIOL; ANTILIPEMIC AGENT; AUTOANTIBODY; CGS 25159; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN VACCINE; COMPLEMENTARY RNA; DEPSIPEPTIDE; FLUORESCENT DYE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOFLAVAN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MONOCLONAL ANTIBODY; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; POLYCYCLOPROPANE; SCH 58149; TETANUS TOXIN; TRIACYLGLYCEROL; U 106305; UNCLASSIFIED DRUG; VACCINE; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DIAGNOSTIC VALUE; DRUG EFFECT; FEMALE; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART PROTECTION; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LABORATORY; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RISK ASSESSMENT; STANDARDIZATION;

ANIMALIA;

EID: 0033645575     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2000.139     Document Type: Article

References (51)

1. Plasma cholesteryl ester transfer protein
2. Molecular genetics of plasma cholesteryl ester transfer protein
3. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation
4. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency
5. Compound heterozygote of cholesteryl-ester transfer protein deficiency in a patient with hyperal-phalipoproteinemia
6. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol
7. Mutations in cholesteryl ester transfer protein and hepatic lipase in a North American population
8. A polymorphic site in the 3' untranslated region of the cholesteryl ester transfer protein (CETP) gene is associated with low CETP activity
9. Multiple RFLP's at the human cholesteryl ester transfer protein (CETP) locus
10. An Stul RFLP at the human cholesteryl ester transfer protein (CETP) locus
11. EcoNI polymorphism in the human cholesteryl ester transfer protein (CETP) gene
12. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels
13. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors: Associations between the Taql B RFLP in the CETP gene and smoking and obesity
14. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers
15. Heterogeneity at the CETP gene locus - Influence on plasma CETP concentrations and HDL cholesterol levels
16. Polymorphisms of the gene encoding cholesterol ester transfer protein and serum lipoprotein levels in subjects with and without coronary heart disease
17. Polymorphisms of the gene coding for the cholesteryl ester transfer protein and plasma lipid levels in Italian and Greek migrants to Australia
18. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
19. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
20. High-density lipoprotein. The clinical implications of recent studies
21. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
22. Contribution of glycaemic control, endogenous lipoproteins and cholesteryl ester transfer protein to accelerated cholesteryl ester transfer in IDDM
23. Changes in high density lipoprotein subfraction lipids during neutral lipid transfer in healthy subjects and in patients with insulin-dependent diabetes mellitus
24. Increased cholesteryl ester transfer activity in complicated type 1 (insulin-dependent) diabetes mellitus: Its relationship with serum lipids
25. Accelerated cholesteryl ester transfer in patients with insulin dependent diabetes mellitus
26. Accelerated cholesteryl ester transfer in non-insulin dependent diabetes mellitus
27. Cholesterol ester transfer and high-density lipoprotein conversion in normolipidemic, hypercholesterolemic, and hypertriglyceridemic non-insulin-dependent diabetics
28. Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density and low density lipoproteins in patients with non-insulin-dependent diabetes mellitus
29. Alterations in composition and concentration of lipoproteins and elevated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus (NIDDM)
30. Increased esterification of cholesterol and transfer of cholesteryl ester to apo B-containing lipoproteins in Type 2 diabetes: Relationship to serum lipoproteins A-I and A-II
31. Elevated plasma cholesteryl ester transfer in NIDDM: Relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein
32. Accelerated cholesteryl ester transfer in dyslipidemic plasma: Role of cholesteryl ester transfer protein
33. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia
34. Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia
35. Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men
36. Plasma lipid transfer protein as a determinant of the atherogenecity of monkey plasma lipoproteins
37. Plasma lipid transfer proteins
38. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein
39. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol
40. Exercise training decreases plasma cholesteryl ester transfer protein
41. Association of cholesteryl ester transfer protein-TaqlB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: The Framingham Study
42. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: Role of Sp1/Sp3 in transcriptional regulation
43. Cholesteryl ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men
44. Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size - Use of a novel tetranucleotide repeat within the CETP promoter
45. Inhibition of cholesteryl ester transfer protein activity in hamsters alters HDL lipid composition
46. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits
47. A depsipeptide fungal metabolite inhibitor of cholesteryl ester transfer protein
48. Inhibition of cholesterol ester transfer protein by CGS 25 159 and changes in lipoproteins in hamsters
49. Cholesterol ester transfer protein inhibition by PD 140195
50. Low-fat and high-monounsaturated fatty acid diets decrease plasma cholesterol ester transfer protein concentrations in young, healthy, normolipemic men
51. Regulation of cholesteryl ester transfer protein (CETP) activity: Review of in vitro and in vivo studies